The Lancet. Rheumatology
Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial.
Andrew P Cope, Marianna Jasenecova, Joana C Vasconcelos, Sumera Qureshi, Karin A van Schie, Andrew Filer, Karim Raza, Maria Antonietta D'Agostino, Iain B McInnes, Stefan Siebert, John D Isaacs, Arthur G Pratt, Benjamin A Fisher, Christopher D Buckley, Paul Emery
Published: 202610.1016/S2665-9913(25)00371-6
Abstract
BACKGROUND: Clinical trials aimed at preventing rheumatoid arthritis in individuals at risk have had variable results. The long-term outcomes of disease interception, however, are not known. We aimed to examine the long-term effect of therapeutic int…
Preview only. Read the full abstract at the source